What is Fatty Liver Disease?

Dr. Michell Shiffman of Bon Secours' Liver Institute of Virginia

Dr. Michell Shiffman of Bon Secours' Liver Institute of Virginia

Non-alcoholic fatty liver disease (NAFD) is one of the most common disorders of the liver.  NAFD is one of the features of the metabolic syndrome which includes type 2 diabetes, hypertension, elevated serum cholesterol, obesity and polycystic ovary disease.  Most patients with NAFD do not have all features of the metabolic syndrome; but having at least 2 other features is very common.

We use the term NAFD to differentiate this from alcohol induced fatty liver disease.  Two types of NAFD exist.  Simple fatty liver or steatosis.  In this case fat accumulates within the liver but does not cause liver injury.  The vast majority of these patients continue to have fat within the liver but the amount of fat does not change over decades and does not lead to liver damage.  The other form of NAFD is non-alcoholic steatohepatitis or NASH.  IN NASH the fat actually causes liver injury and this leads to scarring of the liver which increases over many years to cause cirrhosis.  Patients with NASH tend to have elevated liver enzymes in the blood and type 2 diabetes.  Patients with simple steatosis tend to have normal liver enzymes and do not have diabetes.  There is currently no data to suggest that patients with simple steatosis can develop NASH.  Patients have either one form of NAFLD or the other.

Many patients are found to have NAFD because they have undergone an imaging test of the liver such as an ultrasound or CT scan.  However, such scans cannot differentiate whether this is simple steatosis or NASH.  This can only be accomplished by performing a liver biopsy and examining  a small piece of the liver under the microscope.  Not all the patients with NAFD require a liver biopsy.  Whether a liver biopsy will be helpful in the evaluation and management of a patient suspected of having NAFD can only be determined after a careful evaluation.  This can be provided by Dr Shiffman or his staff at the Liver Institute of Virginia.

No treatment is required for patients with simple steatosis since this does not cause liver injury.  The best treatment for NASH is weight loss and better control of diabetes.  Weight loss reduces the amount of fat within the liver.  This is true whether the patient has either simple steatosis or NASH.  Weight loss in patients with NASH has been shown to reduce liver injury.  In patients with morbid obesity and NASH, weight loss surgery has also been shown to reduce liver injury.  More recently, Vitamin E has also been shown to reduce liver injury in patients with NASH.

Several new medications are currently being evaluated for patients with NASH.  These new experimental treatments will soon be available at the Liver Institute of Virginia.

+ Learn about clinical trials being conducted at the Liver Institute of Virginia
+ Find out about other diseases of the liver

This entry was posted in Bon Secours News, Bon Secours Specialties, General News, Health News & Information, Healthy Communities, Liver Health and tagged , , , , , on by .

About Dr.MLShiffman

Dr. Mitchell Shiffman is the Bon Secours expert on liver disease and liver treatments for Virginia. Prior to joining Bon Secours, Dr. Shiffman was a professor of Medicine at Virginia Commonwealth University (VCU) in Richmond, VA. He was the Chief of the Hepatology Section and Medical Director of the Liver Transplant Program at the VCU Medical Center from 1989 until 2009. During his 20 years at the VCU Medical Center Dr. Shiffman built and directed one of the most respected and productive hepatology programs in the United States. Dr. Shiffman is recognized as one of the world’s leaders in the field of Hepatology. His particular area of research is viral hepatitis. He has been involved with and/or directed numerous clinical trials to develop new and better treatments for viral hepatitis B and C. Dr. Shiffman is a regular speaker on the treatment of viral hepatitis, the management of various liver disorders, and issues related to liver transplantation at regional, national and international society meetings. He has published over 200 articles in medical journals related to the treatment of liver diseases and has edited two books on this topic. In addition, he has contributed to various HCV educational resources including an HCV educational kit. Dr. Shiffman is also a widely recognized expert consultant to pharmaceutical companies on the treatment of liver disease. Dr. Shiffman holds a Bachelor of Arts from State University of New York at Buffalo, a Master of Science in physiology from the University of New Mexico School of Medicine in Albuquerque, N.M. and his Doctor of Medicine from State University of New York Upstate Medical Center in Syracuse, N.Y. He completed his internship and residency in internal medicine and fellowship training in gastroenterology and hepatology at the Medical College of Virginia Hospitals in Richmond, VA. Dr. Shiffman is a member of many professional organizations including: the American College of Gastroenterology, American College of Physicians, the American Gastroenterological Association, American Society for the Study of Liver Diseases, American Society of Transplantation, European Association for the Study of the Liver, International Liver Transplantation Society, Richmond Academy of Medicine, Virginia Medical Society and the Virginia Gastrointestinal Society. He was a member of the Board of Trustees with the American College of Gastroenterology from 2003-2009.

Speak Your Mind